Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease

Mov Disord. 2012 Jan;27(1):132-5. doi: 10.1002/mds.23805. Epub 2011 Nov 14.

Abstract

Background: The A-allele of the catechol-O-methyltransferase (COMT) Val158Met polymorphism is associated with decreased enzymatic activity and higher dopamine availability.

Methods: We studied 219 patients with PD who were free of dyskinesias at baseline and underwent thorough annual examinations.

Results: The A-allele of the COMT Val158Met polymorphism was related to an increased risk of developing dyskinesias during follow-up, in a dose-dependent manner (adjusted hazard ratios for the AG and AA genotypes [compared to GG]: 2.09 [95% confidence interval (CI), 1.07-4.06] and 2.81 [CI, 1.43-5.54], respectively).

Conclusions: This finding suggests that genetic factors may affect susceptibility to dyskinesias in PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antiparasitic Agents / adverse effects
  • Catechol O-Methyltransferase / genetics*
  • Cohort Studies
  • Dyskinesia, Drug-Induced / genetics*
  • Dyskinesias / genetics
  • Female
  • Genetic Predisposition to Disease*
  • Genotype
  • Humans
  • Male
  • Methionine / genetics*
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Parkinson Disease / genetics*
  • Polymorphism, Genetic / genetics*
  • Proportional Hazards Models
  • Valine / genetics*

Substances

  • Antiparasitic Agents
  • Methionine
  • Catechol O-Methyltransferase
  • Valine